A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder - Concepedia

Concepedia

Publication | Open Access

A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder

DOI Full Paper Access

48

Citations

0

References

2020

Year

G. Joel DeCastro, Wilson Sui, Jamie S. Pak, Shing M. Lee, Dara Holder, Max M. Kates, Renu K. Virk, Charles G. Drake, Christopher B. Anderson, Bridget James,

The Journal of Urology

Abstract

In this high risk and highly pretreated cohort of bacillus Calmette-Guérin unresponsive or recurrent/relapsing nonmuscle invasive bladder cancer cases combination intravesical cabazitaxel, gemcitabine and cisplatin was a well tolerated and potentially effective regimen.